Quanterix earnings release, August 10, 2026
Quanterix Releases Financial Results for the Second Quarter of 2026
Reports $32.9 million in revenue and $96.9 million of cash and marketable securities
Company accelerating initiatives to drive commercial effectiveness
Revises financial outlook for 2026 and extends date for attaining cash-flow break-even
BILLERICA,
Mass. – August 10, 2026
-- Quanterix Corporation
(NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026.
“We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued market softness. We are taking immediate and significant action to improve commercial performance, including reorganizing our teams and adding seasoned leadership to sharpen accountability, accelerate execution, and improve operating results in the second half and beyond,” said Everett Cunningham, President & CEO of Quanterix. “We remain confident in the strength and differentiated positioning of both our research tools and diagnostics businesses, especially with enhanced commercial leadership and discipline enabling a renewed focus on returning to sustained growth. Our capabilities in ultra-sensitive protein-detection in blood and high plex spatial analysis in tissue, combined with a differentiated multi-analyte approach, position us well across targeted translational research and diagnostics. With strategic Diagnostics investments underway, our management team can now focus on achieving key milestones in Alzheimer’s disease testing, including completing three clinical utility studies and advancing our FDA roadmap.”
Second Quarter Financial Highlights
• Revenue of $32.9 million, an increase of 34% compared to $24.5 million in the prior year.
• GAAP gross margin of 38.5%, as compared to 40.9% in the prior year. Adjusted gross margin (non-GAAP) of 47.9% compared to 41.8% in the prior year. Prior year GAAP margins are updated to reflect a change in accounting policy in Q1’26 related to shipping and handling costs. Shipping and handling costs for product sales are now recorded in the cost of product revenue in the Company’s GAAP financials.
• Adjusted EBITDA (non-GAAP) loss of $10.0 million, compared to $13.7 million in the prior year.
• The Company ended the second quarter with $96.9 million of cash, cash equivalents, marketable securities, and restricted cash. Adjusted cash usage, after accounting for integration and certain employee separation costs of $1.7 million, was $4.0 million in the second quarter, a decrease in usage of $10.8 million from the first quarter of 2026.
• The Company completed its ERP system integration, the final step of the Akoya acquisition integration program that realized $85 million in savings on an annualized basis.
• Quanterix incurred a $26.9 million goodwill impairment related to the Akoya acquisition as required under GAAP accounting based on recent circumstances within the business. The adjustment does not impact operations or liquidity.
Operational and Business Highlights
• Quanterix finished building its senior management team ahead of its anticipated higher growth phase, especially in the Diagnostics business. Jim Gute was named Chief Commercial Officer, as announced separately today. Industry veteran Geoff Albrecht was appointed Senior Vice President and General Manager of Diagnostics, Anthony Catalano was named Chief Operating Officer and Jason Faessler was appointed Chief Financial Officer.
• Several milestones to advance clinical adoption of blood-based Alzheimer’s testing were announced, including commercial insurance coverage. Beginning July 1, 2026, members covered under Anthem Blue Cross and Blue Shield medical policies can receive coverage for qualifying blood-based biomarker testing, including Quanterix’s Lucent AD® Complete, when medical necessity criteria are met.
• A peer-reviewed study evaluating Lucent AD® Complete alongside an algorithmic immunoprecipitation mass spectrometry (IP-MS) approach on a shared patient cohort demonstrated the high diagnostic parity and three-fold reduced diagnostic ambiguity provided by Quanterix’s multi-analyte algorithmic blood testing approach.
• New clinical data presented at the Alzheimer’s Association International Conference (AAIC) 2026 highlighted how multi-biomarker testing improves detection of early Alzheimer's and provides a more comprehensive framework for guiding patient care.
• Quanterix was selected as a Co-Investigator institution in the PD-BUILD program, in the Aligning Science Across Parkinson’s Collaborative Research Network 2026 expansion, supported by The Michael J. Fox Foundation. This multi-year grant funds development and deployment of high-quality biomarker tools aimed at enabling earlier detection, improved patient stratification, and more effective monitoring of Parkinson’s disease in clinical research. Quanterix and its Simoa platform will develop and distribute validated single-plex and multiplex biomarker assays to Parkinson’s disease researchers globally.
• Quanterix launched Simoa® Ultra-Sensitive Immunoassay NPTX2, an important emerging synaptic biomarker.
• Two new spatial products were launched: Spatial Molecular Barcoding kit for the Phenocycler Fusion for early access and Spatial Spectral DAPI 2.0 for the Phenoimager HT.
2026 Business Outlook... (truncated)ash balance, compared to $100 million previously. The company expects to end the year with no debt.
Conference Call
In conjunction with this announcement, the Company will host a conference call today, August 10, 2026, at 8:30 AM ET. The dial-in number for USA & Canada is Toll-Free (800) 715-9871 or (646) 307-1963 and the conference ID is 9896910.
Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at https://ir.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.
About Quanterix
Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. Learn more at www.quanterix.com.
Financial statements
Income Statement
Three Months Ended June 30, — (unaudited, amounts in thousands, except per share data)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Revenues: | Product revenue | 23,476 | 16,832 | 48,956 | 37,572 |
| Revenues: | Service and other revenue | 9,018 | 7,112 | 19,394 | 15,935 |
| Revenues: | Collaboration and license revenue | 412 | 532 | 972 | 1,303 |
| Revenues: | Total revenues | 32,906 | 24,476 | 69,322 | 54,810 |
| Costs of goods sold and services: | Cost of product revenue | 14,621 | 10,594 | 29,761 | 21,935 |
| Costs of goods sold and services: | Cost of service and other revenue | 5,611 | 3,881 | 11,320 | 8,035 |
| Costs of goods sold and services: | Total costs of goods sold and services | 20,232 | 14,475 | 41,081 | 29,970 |
| Costs of goods sold and services: | Gross profit | 12,674 | 10,001 | 28,241 | 24,840 |
| Operating expenses: | Research and development | 7,821 | 9,081 | 15,144 | 19,117 |
| Operating expenses: | Selling, general and administrative | 27,350 | 30,350 | 57,121 | 61,520 |
| Operating expenses: | Impairment and restructuring costs | 26,934 | 7,670 | 46,769 | 7,670 |
| Operating expenses: | Total operating expenses | 62,105 | 47,101 | 119,034 | 88,307 |
| Operating expenses: | Loss from operations | -49,431 | -37,100 | -90,793 | -63,467 |
| Other income (expense), net: | Interest income | 761 | 2,692 | 1,653 | 5,962 |
| Other income (expense), net: | Change in fair value of contingent liabilities | -79 | 4,273 | 1,422 | 3,894 |
| Other income (expense), net: | Other income (expense), net | -239 | 49 | 21,182 | 108 |
| Other income (expense), net: | Loss before income taxes | -48,988 | -30,086 | -66,536 | -53,503 |
| Other income (expense), net: | Income tax benefit | 54 | 73 | 61 | 2,986 |
| Other income (expense), net: | Net loss | -48,934 | -30,013 | -66,475 | -50,517 |
| Other income (expense), net: | Net loss per common share, basic and diluted | -1.04 | -0.77 | -1.41 | -1.3 |
| Other income (expense), net: | Weighted-average common shares outstanding, basic and diluted | 47,167 | 38,893 | 47,068 | 38,801 |
Income Statement
Three Months Ended June 30, — (unaudited, amounts in thousands, except percentages)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | |
|---|---|---|---|---|
| Net loss | -48,934 | -30,013 | -66,475 | -50,517 |
| Interest income | -761 | -2,692 | -1,653 | -5,962 |
| Income tax benefit | -54 | -73 | -61 | -2,986 |
| Depreciation and amortization | 6,134 | 1,999 | 11,737 | 4,187 |
| Stock-based compensation expense (1) | 4,212 | 5,373 | 8,388 | 10,834 |
| Acquisition and integration related costs (2) | 852 | 4,139 | 2,004 | 7,717 |
| Earnout recorded as compensation expense (3) | 4,156 | 7,900 | ||
| Changes in contingent liabilities (4) | 79 | -4,273 | -1,422 | -3,894 |
| Impairment and employee separation costs (5) | 28,483 | 7,670 | 49,271 | 7,670 |
| Income from contract termination (6) | -21,596 | |||
| Adjusted EBITDA (non-GAAP) | -9,989 | -13,714 | -19,807 | -25,051 |
| Total revenues | 32,906 | 24,476 | 69,322 | 54,810 |
| Adjusted EBITDA margin (non-GAAP) (adjusted EBITDA as a % of revenue) | -30.4 | -56 | -28.6 | -45.7% |
Income Statement
Three Months Ended June 30, — (unaudited, amounts in thousands, except percentages)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | |
|---|---|---|---|---|
| Gross profit | 12,674 | 10,001 | 28,241 | 24,840 |
| Purchase accounting impact on inventory and property and equipment (1) | 203 | 402 | ||
| Amortization of acquired intangible assets (2) | 2,886 | 234 | 5,658 | 461 |
| Adjusted gross profit (non-GAAP) | 15,763 | 10,235 | 34,301 | 25,301 |
| Total revenues | 32,906 | 24,476 | 69,322 | 54,810 |
| Gross margin (gross profit as % of total revenues) | 38.5% | 40.9% | 40.7% | 45.3% |
| Adjusted gross margin (non-GAAP) (adjusted gross profit as % of total revenues) | 47.9% | 41.8% | 49.5% | 46.2% |
| Total operating expenses | 62,105 | 47,101 | 119,034 | 88,307 |
| Purchase accounting impact on property and equipment (1) | -969 | -1,192 | ||
| Amortization of acquired intangible assets (2) | -50 | -127 | ||
| Acquisition and integration related costs (3) | -852 | -4,139 | -2,004 | -7,717 |
| Earnout recorded as compensation expense (4) | -4,156 | -7,900 | ||
| Impairment and employee separation costs (5) | -28,484 | -7,670 | -49,270 | -7,670 |
| Adjusted total operating expenses (non-GAAP) | 31,750 | 31,136 | 66,441 | 65,020 |
| Loss from operations | -49,431 | -37,100 | -90,793 | -63,467 |
| Purchase accounting impact on inventory and property and equipment (1) | 1,172 | 1,594 | ||
| Amortization of acquired intangible assets (2) | 2,936 | 234 | 5,785 | 461 |
| Acquisition and integration related costs (3) | 852 | 4,139 | 2,004 | 7,717 |
| Earnout recorded as compensation expense (4) | 4,156 | 7,900 | ||
| Impairment and employee separation costs (5) | 28,484 | 7,670 | 49,270 | 7,670 |
| Adjusted loss from operations (non-GAAP) | -15,987 | -20,901 | -32,140 | -39,719 |
Balance Sheet
June 30, 2026 — (unaudited, amounts in thousands, except per share data)
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 44,169 | 29,839 |
| Current assets: | Marketable securities | 49,360 | 88,393 |
| Current assets: | Accounts receivable, net of allowance for expected credit losses | 22,345 | 29,972 |
| Current assets: | Inventory | 47,601 | 54,763 |
| Current assets: | Prepaid expenses and other current assets | 7,576 | 9,290 |
| Current assets: | Total current assets | 171,051 | 212,257 |
| Current assets: | Restricted cash | 3,348 | 3,341 |
| Current assets: | Property and equipment, net | 20,002 | 23,672 |
| Current assets: | Intangible assets, net | 105,782 | 131,787 |
| Current assets: | Goodwill | 26,376 | |
| Current assets: | Operating lease right-of-use assets | 15,053 | 16,664 |
| Current assets: | Other non-current assets | 4,391 | 4,669 |
| Current assets: | Total assets | 319,627 | 418,766 |
Cash Flow
Six Months Ended June 30, — (unaudited, amounts in thousands)
| Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|
| Cash flows from operating activities: | Net loss | -66,475 | -50,517 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Depreciation and amortization expense | 11,737 | 4,187 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Credit losses on accounts receivable | 516 | -262 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Accretion of marketable securities | -202 | -1,567 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Operating lease right-of-use asset amortization | 1,601 | 850 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock-based compensation expense | 8,739 | 10,834 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Impairment | 46,769 | 6,374 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Change in fair value of contingent liabilities | -1,422 | -3,894 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Recognition of off-market liability | -13,975 | |
| Adjustments to reconcile net loss to net cash used in operating activities: | Other operating activity | -558 | -370 |
| Changes in assets and liabilities: | Accounts receivable | 6,817 | 9,476 |
| Changes in assets and liabilities: | Inventory | 7,652 | 2,993 |
| Changes in assets and liabilities: | Prepaid expenses and other current assets | 1,561 | 1,942 |
| Changes in assets and liabilities: | Accounts payable | -6,763 | 2,796 |
| Changes in assets and liabilities: | Accrued compensation and benefits, accrued expenses, and other current liabilities | -6,377 | 1,605 |
| Changes in assets and liabilities: | Deferred revenue | -9,163 | 583 |
| Changes in assets and liabilities: | Net change in other operating assets and liabilities | -3,683 | -4,573 |
| Changes in assets and liabilities: | Net cash used in operating activities | -23,226 | -19,543 |
| Cash flows from investing activities: | Purchases of marketable securities | -8,245 | -30,245 |
| Cash flows from investing activities: | Proceeds from sales and maturities of marketable securities | 47,354 | 135,874 |
| Cash flows from investing activities: | Purchases of property and equipment | -183 | -2,033 |
| Cash flows from investing activities: | Acquisitions, net of cash acquired | -8,954 | |
| Cash flows from investing activities: | Net cash provided by investing activities | 38,926 | 94,642 |
| Cash flows from financing activities: | Deferred acquisition payments | -1,439 | |
| Cash flows from financing activities: | Principal payments on financing leases | -171 | |
| Cash flows from financing activities: | Proceeds from common stock issued under stock plans | 340 | 668 |
| Cash flows from financing activities: | Payments for employee taxes withheld on stock-based compensation awards | -27 | -1,004 |
| Cash flows from financing activities: | Net cash used in financing activities | -1,297 | -336 |
| Cash flows from financing activities: | Net increase in cash, cash equivalents, and restricted cash | 14,403 | 74,763 |
| Cash flows from financing activities: | Effect of exchange rate changes on cash, cash equivalents, and restricted cash | -66 | 1,455 |
| Cash flows from financing activities: | Cash, cash equivalents, and restricted cash at beginning of period | 33,180 | 59,319 |
| Cash flows from financing activities: | Cash, cash equivalents, and restricted cash at end of period | 47,517 | 135,537 |
Full release
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix’s future business outlook, operations, strategy and financial performance, including statements related to our expectations about consistent profitable revenue growth and achieving cash flow breakeven performance, the development and commercialization of our products, and under the header “2026 Business Outlook.”. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix’s future business, operations, strategy and financial performance: risks related to the impact of changes in U.S. government policies, including impacts of tariffs and reductions in federal research funding; risks associated with the anticipated timing for launch of, and features of, Quanterix’s next-generation instruments to upgrade its existing platforms; risks related to Quanterix’s ability to improve existing diagnostics and develop new diagnostic tests and tools; risks related to Quanterix’s ability to successfully penetrate the diagnostics market; risks related to Quanterix’s ability to retain and expand its customer base and achieve sufficient market acceptance of its products; risks related to the ability of Quanterix’s contract manufacturers and suppliers to reliably and consistently manufacture and supply our instruments; risks that Quanterix may fail to realize the anticipated benefits from its recent acquisitions of Emission, Inc. and Akoya Biosciences, Inc.; risks that Quanterix’s estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect; risks related to Quanterix’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures; and risks related to defects or other quality issues in Quanterix’s products that could lead to unforeseen costs, product recalls, adverse regulatory actions, negative publicity and litigation. Additional factors that could cause results to differ materially from those described above can be found in the periodic reports filed by Quanterix with the SEC, including the “Risk Factors” sections contained therein, which are available on the SEC’s website at www.sec.gov.
All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix’s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.
FINANCIAL HIGHLIGHTS